logo-loader
viewPreveCeutical Medical Inc

PreveCeutical gets default judgement in part of civil claim

Preveceutical said it had received a default judgment against Essos Corporate Services Inc and Detona Capital

Law book
Preveceutical brought the action last year with the Supreme Court of British Columbia

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences firm, revealed it had prevailed so far in part of a previously reported civil claim.

The firm said that it had obtained a default judgement against Essos Corporate Services Inc. (Essos) and Detona Capital Corp. (Detona).

The firm brought the action to the Supreme Court of British Columbia late last year, against a group of defendants, including Essos and Detona, for various things, including fraudulent misrepresentation and breach of contract in connection with services that the defendants failed to provide to PreveCeutical.

READ: PreveCeutical Medical files civil claim against Bridgemark Group

Also, it covered various consulting agreements and subscription agreements entered into between PreveCeutical and certain of the defendants.

Default judgments are ordered when one party has failed to file and serve a response to the claim within the time allowed by the rules.

"The default judgement shows due process and that proceedings are moving forward. We have confidence in the judicial system and thank our shareholders for their continued patience while we see this through," said PreveCeutical's chairman and CEO, Stephen Van Deventer.

The defendants consist of Aly Babu Mawji, Justin Liu, BridgeMark Financial Corp., Rockshore Advisors Ltd. (formerly known as, Cam Paddock Enterprises Inc.), Detona Capital Corp., Escher Invest SA, Essos Corporate Services Inc., Jarman Capital Inc., JCN Capital Corp., Kendl Capital Limited, Lukor Capital, Northwest Marketing and Management Inc., Sway Capital Corp. and Tryton Financial Corp.

Damages and costs to be awarded to Preveceutical and against Essos and Detona are yet to be decided by the court.

The firm also noted it was continuing to pursue its claims against the other defendants.

Preveceutical did not immediately respond to a request for comment.

Essos Corporate Services Inc and Detona Capital Corp could not be reached for comment.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

Quick facts: PreveCeutical Medical Inc

Price: 0.015 CAD

CSE:PREV
Market: CSE
Market Cap: $5.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

5 days, 16 hours ago

2 min read